biostudies-literatureUnknown21(4)Ramachandran PFatty liver disease progresses through stages of fat accumulation and inflammation to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and eventually hepatocellular carcinoma (HCC). Currently available diagnostic tools for HCC lack sensitivity and specificity. In this study, we investigated the use of circulating serum glycoproteins to identify a panel of potential prognostic markers that may be indicative of progression from the healthy state to NASH and further to HCC. Serum samples were processed and analyzed using a novel high-throughput glycoproteomics platform. Our initial dataset contained healthy, NASH, and HCC serum samples. We analyzed 413 glycopeptides, representing 57 abundant serum proteins, and compared among the three phenotypes. We studied the normalized abundanJournal of proteome research1083-1094https://www.ebi.ac.uk/biostudies/studies/S-EPMC8981307biostudies-literatureSerum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.PMC8981307Huang HHLindpaintner KSerie DRamachandran PZhou BRice RXu GfalseSerum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.Fatty liver disease progresses through stages of fat accumulation and inflammation to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and eventually hepatocellular carcinoma (HCC). Currently available diagnostic tools for HCC lack sensitivity and specificity. In this study, we investigated the use of circulating serum glycoproteins to identify a panel of potential prognostic markers that may be indicative of progression from the healthy state to NASH and further to HCC. Serum samples were processed and analyzed using a novel high-throughput glycoproteomics platform. Our initial dataset contained healthy, NASH, and HCC serum samples. We analyzed 413 glycopeptides, representing 57 abundant serum proteins, and compared among the three phenotypes. We studied the normalized abundan2022-01-01T00:00:00Z2022 Apr2025-04-19T21:50:08.718Z2025-04-19T21:50:08.718ZS-EPMC89813073528680310.1021/acs.jproteome.1c00965